A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
Tang
JingYan
J
Department of Hematology/Oncology, Xin Hua Hospital/Shanghai Children's Medical Center, Shanghai Second Medical University. yantfk@online.sh.cn
Xue
Huiliang
H
Pan
Ci
C
Chen
Jing
J
Gu
LongJun
L
Zhao
HuiJun
H
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002681:China; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage*; D000077863:Homoharringtonine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality*; D016019:Survival Analysis; D016896:Treatment Outcome
D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D005047:Etoposide